University of Vermont

College of Medicine

Department of Neurological Sciences

Bio for James T. Boyd, M.D.
James T. Boyd, M.D.

James T. Boyd, M.D.

Associate Professor
Department of Neurological Sciences

Contact Information
Office Location:
University of Vermont, College of Medicine, 1 So. Prospect Street, UHC - Arnold 2, Burlington, Vermont 05401


1996-2000: M.D., Memorial University of Newfoundland, St. John's, Newfoundland, Canada
1992-1996: B.S., Biochemistry, State University of New York – Geneseo College, Geneseo, NY

Academic Interests

Neuroprotective therapies in Parkinson's disease
Behavioral changes in movement disorders
Nicotine in Parkinson's disease


Parkinson's disease and other movement disorders
Deep brain stimulation
Botulinum toxin injections

Academic Appointments

2012-Present: Associate Professor of Neurological Sciences, University of Vermont College of Medicine
2005-2012: Assistant Professor of Neurology, University of Vermont College of Medicine

Clinical Appointments

2005-Present: Attending Physician, University of Vermont Medical Center, Burlington, VT

Board Certification

2005: Board certification in Neurology, American Board of Psychiatry & Neurology
2007: Board certification in the Subspecialty of Clinical Neurophysiology, American Board of Psychiatry & Neurology


2004-Present: Medical Licensure, State of Vermont

Awards and Honors

2010: Parkinson Study Group - Mentored Clinical Research Award
2004: Huntington Mavor Memorial Award - Department of Neurology University of Vermont.
2004: Arnold P.Gold Foundation - Humanism and Excellence in Teaching Award
2003: Resident of the Year Award - Department of Neurology, University of Vermont
1999: Bruce A. Fraser Scholarship for academic achievement
1996: Tri-Beta Biology National Honor Society
1993: John Hablitz Memorial Scholarship for academic achievement

Professional Activities

2013-Present: Member, Huntington Study Group (HSG)
2010-2013: Parkinson Study Group - Mentoring Committee
2009-Present: Member, American Society for Experimental NeuroTherapeutics (ASENT)
2009-2015: Committee on Human Research in the Medical Sciences (UVM Institutional Review Board)
2008-Present: Careers in Medicine - UVM Medical Student Advisor
2008-Present: Member, Parkinson Study Group (PSG)
2007-Present: Member, International Society for Posture and Gait Research (ISPGR)
2006-2010: Faculty Advisor, Student Interest Group in Neurology (SIGN)
2005-2010: Senator, UVM Faculty Senate
2004-Present: Member, Vermont State Medical Society
2004-Present: Member, Movement Disorders Society (MDS)
2001-Present: Member, Northern New England Neurological Society (NNENS)
2001-Present: Member, American Academy of Neurology (AAN)

Research Grants

2014-Present: “Understanding Voice in Parkinson’s Disease.” Sponsor: Binter Center Undergraduate Research Award. Role: Supervisor/Co-investigator. Principal Investigator: Suzanne Calhoun.

2014-Present: “Dynamic Limb Selection During Step Initiation With Parkinson’s Disease.” Sponsor: 2014 Binter Center Research Award. Role: Co-investigator. Principal Investigator: Jesse Jacobs, PhD, Co-investigator: Roman Popov.

2014-Present: “An open-label, long term safety study of SD-809 ER in subjects with chorea associated with Huntington disease.” Sponsor: Auspex Pharmaceuticals (NCT01897896). Role: Site Principal Investigator. Principal Investigator: Huntington Study Group (HSG).

2014-Present: “A randomized, double-blind, placebo controlled, fixed-dose study of SD-809 (deutetrabenazine) for the treatment of moderate to severe tardive dyskinesia.” Sponsor: Auspex Pharmaceuticals (NCT02195700). Role: Site Principal Investigator. Principal Investigator: Karissa Sanabria, PhD.

2012-Present: “Correlation of primidone metabolites and essential tremor control: A pilot trial.”Sponsor: University of Vermont, Department of Neurology. Role: Principal Investigator.

2011-Present: “A randomized, placebo-controlled, multi-center study to assess the disease modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD).” Sponsor: MJ Fox Foundation (KKS-135). Role: Co-investigator/United States Principal Investigator. Principal Investigator: Wolfgang Oertel, MD.

2010-Present: “Nicotine in the treatment of impulsivity in Parkinson’s disease: A pilot study.” Sponsor: Parkinson Study Group/Parkinson’s Disease Foundation. Role: Principal Investigator. Co-investigators: Newhouse PA, Potter AS.


Jacobs J, Boyd JT, Hogarth P, Horak FB. Domains and correlates of clinical balance impairment associated with Huntington's disease. Gait Posture. 2015 Mar 9.

Parashos SA, Elm J, Boyd JT, Chou KL, Dai L, Mari Z, Morgan JC, Sudarsky L, Wielinski CL. Validation of an ambulatory capacity measure in Parkinson disease: a construct derived from the unified Parkinson's disease rating scale. J Parkinsons Dis. 2015 Jan 1;5(1):67-73.

Fang JY, Pérez A, Christine CW, Leehey M, Aminoff MJ, Boyd JT, Morgan JC, Dhall R, Nicholas AP, Bodis-Wollner I. Parkinson's disease severity and use of dopaminergic medications. Parkinsonism Relat Disord. 2014 Dec 15.

Boyd, JT, Silverman, DA; Amantadine-induced patulous eustachian tubes in Parkinson's disease. Case Reports in Otolaryngology. 2013 Nov 20.

Boyd JT, Fries TJ, Nagle KJ, Hamill RW. A novel ocular geste antagoniste in cervical dystonia: a case report. Tremor and Other Hyperkinetic Movements. 2013 Nov 14.

To see more of Dr. Boyd's publications, please visit PubMed.

Other Interest

  • Grant support in the last 12 months from: National Institutes of Health, the Michael J. Fox Foundation, and the Frederick C. Binter Center for Parkinson’s Disease and Movement Disorders at the University of Vermont Medical Center.
  • Served as a site principle investigator for AbbVie, Auspex Pharmaceuticals, and Biotie Therapies.
  • Received personal compensation/honoraria from AbbVie, Auspex Pharmaceuticals, and Lundbeck.